CSF1R and Alzheimer disease: Some of these drugs specifically targeted the microglial subgroups in AD, including the p38-MAPK inhibitors Neflamapimod [59] and Losmapimod [60], the NF-κB inhibitor NE3107 [61], and the CSF1R inhibitor Masitinib [62].